Because hepatocellular carcinoma (HCC) almost always occurs in a background of chronic liver disease and has multiple possible therapeutic pathways, treatment requires the expertise of physicians with different areas of specialization. At Penn Medicine we believe the best way to achieve effective and comprehensive care for patients with hepatocellular carcinoma is a multidisciplinary treatment team. Once HCC is diagnosed, there are three key parameters that Penn Medicine uses to draw a pathway for the best therapeutic options. That pathway and the parameters are discussed in this video with Penn Medicine's Dr. Maarouf Hoteit, Director of the Liver Tumor Clinic and Associate Medical Director of Liver Transplantation.
Related Links:
Twitter @PennMDForum
See Dr. Hoteit’s physician profile
Published
August 24, 2021
Created by
BROADCASTMED